Medincell SA
PAR:MEDCL
Intrinsic Value
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. [ Read More ]
The intrinsic value of one MEDCL stock under the Base Case scenario is hidden EUR. Compared to the current market price of 14.7 EUR, Medincell SA is hidden .
Valuation Backtest
Medincell SA
Run backtest to discover the historical profit from buying and selling MEDCL stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Medincell SA
Current Assets | 39.4m |
Cash & Short-Term Investments | 26.8m |
Receivables | 11.5m |
Other Current Assets | 1.1m |
Non-Current Assets | 11.1m |
Long-Term Investments | 3.3m |
PP&E | 5.8m |
Intangibles | 2.1m |
Other Non-Current Assets | -1k |
Current Liabilities | 19.8m |
Accounts Payable | 2m |
Accrued Liabilities | 2m |
Other Current Liabilities | 15.8m |
Non-Current Liabilities | 56.4m |
Long-Term Debt | 53.2m |
Other Non-Current Liabilities | 3.2m |
Earnings Waterfall
Medincell SA
Revenue
|
10.8m
EUR
|
Cost of Revenue
|
-4.3m
EUR
|
Gross Profit
|
6.6m
EUR
|
Operating Expenses
|
-27.9m
EUR
|
Operating Income
|
-21.4m
EUR
|
Other Expenses
|
-5m
EUR
|
Net Income
|
-26.4m
EUR
|
Free Cash Flow Analysis
Medincell SA
MEDCL Profitability Score
Profitability Due Diligence
Medincell SA's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Medincell SA's profitability score is hidden . The higher the profitability score, the more profitable the company is.
MEDCL Solvency Score
Solvency Due Diligence
Medincell SA's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Medincell SA's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MEDCL Price Targets Summary
Medincell SA
According to Wall Street analysts, the average 1-year price target for MEDCL is 18.79 EUR with a low forecast of 14.14 EUR and a high forecast of 23.1 EUR.
Shareholder Return
MEDCL Price
Medincell SA
Average Annual Return | 3.36% |
Standard Deviation of Annual Returns | 41.26% |
Max Drawdown | -70% |
Market Capitalization | 418.7m EUR |
Shares Outstanding | 29 070 600 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 150 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one MEDCL stock under the Base Case scenario is hidden EUR.
Compared to the current market price of 14.7 EUR, Medincell SA is hidden .